de Parades Vincent, Etienney Isabelle, Bauer Pierre, Bourguignon Josée, Meary Nathalie, Mory Benoit, Sultan Samy, Taouk Milad, Thomas Christian, Atienza Patrick
Proctologie Médico-Interventionnelle, Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris, France.
Dis Colon Rectum. 2005 Aug;48(8):1535-41. doi: 10.1007/s10350-005-0030-z.
This prospective study evaluated the efficacy and safety of local formalin application in chronic refractory radiation-induced hemorrhagic proctitis.
All patients were treated under anesthesia by direct application of 4 percent formalin to the affected rectal areas.
The study included 33 patients (17 women) and was conducted between January 1994 and December 2001. There were 11 anal cancers (33 percent), 11 prostate cancers, 9 cervical or endometrial cancers, 1 bladder cancer, and 1 rectal cancer. The mean number of daily rectal bleeds was 2.7 (range, 0.5-15). Nineteen patients (58 percent) were blood transfusion dependent. Twenty-three patients had only one formalin application and 10 patients required a second application because of the persistent bleeding. The treatment was effective in 23 cases (70 percent): 13 patients had complete cessation of bleeding and 10 patients had only minor bleeding. Six anal or rectal strictures occurred: 4 patients had been treated for anal cancer (36 percent) and 2 patients had been treated for other cancers (9 percent). None of the strictures was malignant. Anal incontinence worsened in 5 patients of the 11 who had been treated for anal cancer (45 percent) and occurred in 4 of the 22 other patients (18 percent).
Formalin application is an effective treatment for chronic radiation-induced hemorrhagic proctitis. However, local morbidity is not negligible. This result may be related to the high proportion of anal cancers in the series. In our opinion, therefore, formalin application should be reserved for severe hemorrhagic proctitis refractory to medical treatment and should be thoroughly discussed in cases of anorectal radiation-induced stricture, prior anal incontinence, or treated anal cancer.
本前瞻性研究评估了局部应用福尔马林治疗慢性难治性放射性出血性直肠炎的疗效和安全性。
所有患者在麻醉下接受治疗,将4%的福尔马林直接应用于受影响的直肠区域。
该研究纳入了33例患者(17例女性),研究时间为1994年1月至2001年12月。其中有11例肛门癌(33%)、11例前列腺癌、9例宫颈癌或子宫内膜癌、1例膀胱癌和1例直肠癌。每日直肠出血的平均次数为2.7次(范围为0.5 - 15次)。19例患者(58%)依赖输血。23例患者仅接受了一次福尔马林治疗,10例患者因持续出血需要第二次治疗。治疗在23例患者(70%)中有效:13例患者出血完全停止,10例患者仅出现少量出血。出现了6例肛门或直肠狭窄:4例接受肛门癌治疗的患者(36%),2例接受其他癌症治疗的患者(9%)。所有狭窄均非恶性。在接受肛门癌治疗的11例患者中,有5例(45%)肛门失禁加重,在其他22例患者中有4例(18%)出现肛门失禁。
应用福尔马林是治疗慢性放射性出血性直肠炎的有效方法。然而,局部发病率不可忽视。这一结果可能与该系列中肛门癌的高比例有关。因此,我们认为,福尔马林应用应仅用于对药物治疗难治的严重出血性直肠炎,对于肛门直肠放射性狭窄、既往肛门失禁或已治疗的肛门癌患者,应进行充分讨论。